PET/CT scans: Diagnostic Test: For 68Ga-Trivehexin PET/CT, no special preparation was required. Approximately 50 min after an i.v. administration of \[68Ga\]Ga-Trivehexin with a dose of 1.85-2.22 MBq/kg, and the PET acquisition time was 2.5 min per bed.
Study summary
Malignant tumors are a significant health threat with high incidence and mortality rates, and molecular imaging is crucial for early diagnosis, staging, prognosis evaluation, and therapeutic efficacy assessment. 18F-FDG PET imaging is widely used, but has limitations. Integrin αvβ6 is a promising target for tumor-targeted imaging, as it is only expressed in cancerous or reconstructed epithelial cells. A new PET probe, 68Ga-Trivehexin, targeting integrin αvβ6 has been developed with better affinity and selectivity than previous probes. Clinical data supports its safety and metabolic stability, and future research will explore its diagnostic and staging value in different types of tumors, providing a new and precise evaluation method for malignant tumors.
Eligibility
Sex
ALL
Min age
18 Years
Max age
85 Years
Healthy volunteers
No
Inclusion Criteria:
* Participants with newly diagnosed malignant tumor confirmed by pathology or suspected lung cancer;
* Age ≥18 years, regardless of gender;
* No prior anti-tumor therapy (e.g., chemotherapy, radiotherapy, targeted therapy, or immunotherapy) before PET/CT;
* Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0-1;
* Female subjects of reproductive age, male subjects and their partners agree to use reliable contraceptive measures (e.g., abstinence, birth control pills, injectable contraceptives, or subcutaneous contraceptive implants) until 6 months after the completion of the study;
* Participants should voluntarily consent to the clinical trial, and have the ability to understand and sign an informed consent form.
Exclusion Criteria:
* Known allergy to injection or its excipients;
* Severe liver or renal dysfunction;
* Claustrophobia or other psychiatric disorders;
* History of other malignant tumors;
* Participation in another clinical trial within 30 days prior to PET/CT scan;
* Pregnant or breastfeeding women;
* Refusal to participate or request for withdrawing from the clinical study;
* Other conditions deemed unsuitable for inclusion by investigator.
Primary outcome measure(s)
The diagnostic sensitivity and specificity of 68Ga-Integrin αvβ6 PET/CT in the staging of malignant tumors — 2 years The diagnostic performance of \[68Ga\]Ga-Trivehexin PET/CT and \[18F\]-FDG PET/CT for initial staging will be evaluated and compared using histopathological findings or typical imaging features as reference standard.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.